Alder Biopharmaceuticals (ALDR) Reports Q1 Loss of $5.38/sh

Alder Biopharmaceuticals (NASDAQ: ALDR) reported Q1 EPS of ($5.38), versus ($5.89) reported last year. Revenue for the quarter came in at $4.8 million, versus $4.6 million reported last year.

"During the first quarter we continued to advance our pipeline and in May 2014 we were very pleased to successfully complete our initial public offering, which raised $80.1 million in net proceeds," said Randall C. Schatzman, Ph.D., President and Chief Executive Officer of Alder. "We believe that we are well-positioned to continue to advance our pipeline and look forward to initiating our Phase 2b trial of ALD403, as well as our partner Bristol-Myers Squibb completing the Phase 2b follow-on trial for Clazakizumab and presenting data from the Phase 2 trial for Clazakizumab for the treatment of psoriatic arthritis by the first half of 2015."

For earnings history and earnings-related data on Alder Biopharmaceuticals (ALDR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c